

Clinical Overview of Algal-Docosahexaenoic Acid: Effects on Triglyceride Levels and Other Cardiovascular Risk Factors

Alan S. Ryan, PhD,* Michelle A. Keske, PhD,† James P. Hoffman, MD, and
Edward B. Nelson, MD, PhD

The cardiovascular benefits of fish-derived long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA), and eicosapentaenoic acid are well established. Less studied are specific effects of individual long-chain polyunsaturated fatty acids. Based on data from 16 published clinical trials, this review examines effects of DHA triglyceride (TG) oil derived from algae (algal-DHA) on serum TG levels and related parameters. Study populations included subjects with both normal and elevated TG levels including those with persistent hypertriglyceridemia treated with concomitant 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy. At doses of 1–2 g/d, algal-DHA significantly lowered plasma TG levels (up to 26%) either administered alone or in combination with statins. The reduction in TG levels was markedly greater in hypertriglyceridemic than in normal subjects. Algal-DHA modestly increased plasma levels of both high-density lipoprotein and low-density lipoprotein cholesterol. The increased plasma level of low-density lipoprotein cholesterol was associated with a shift of lipoprotein particle size toward larger, less atherogenic subfractions. In some subjects, blood pressure and heart rate were significantly reduced. Algal-DHA was safe and well tolerated. Unlike fish oil, algal-DHA seldom caused gastrointestinal complaints such as fishy taste and eructation, attributes of importance for patient compliance in high-dose therapy. Regression analysis that showed a linear relationship between baseline TG and magnitude of TG reduction suggests that a study of patients with very high TG levels (>500 mg/dL) is warranted. Future pharmacologic therapies for treating hypertriglyceridemia may include algal-DHA.

Keywords: docosahexaenoic acid, triglycerides, cardiovascular disease, omega-3 fatty acids

INTRODUCTION

Clinical trials have demonstrated that omega-3 long-chain polyunsaturated fatty acids (LC-PUFA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) provide important cardioprotective benefits. These LC-PUFA not only lower triglyceride (TG) levels but also provide modest lowering of both blood

pressure and heart rate in normotensive and mildly hypertensive individuals,^{1–3} reduce significantly the risk of sudden death,^{4,5} reduce inflammation,⁶ reduce the long-term risk of atherosclerosis and ischemic heart disease,⁷ contribute to maintenance of graft patency after coronary artery bypass surgery,⁸ and improve endothelial and vascular function.^{9,10} Epidemiological studies have demonstrated an inverse association between the intake of LC-PUFA from fish and coronary heart disease mortality.^{4,11–13} The cardioprotective effect of LC-PUFA is particularly strong among high-risk individuals with a previous myocardial infarction.⁵ The American Heart Association recommends that individuals with documented coronary artery disease take at least 1 g/d of DHA plus EPA.¹⁴ For individuals with hypertriglyceridemia (HTG), 2–4 g/d

Martek Biosciences Corporation, Columbia, MD.

†Present address: Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia.

*Address for correspondence: Martek Biosciences Corporation, 6480 Dobbins Road, Columbia, MD 21045. E-mail: alryan@martek.com

is recommended.¹⁴ Fatty fish such as tuna, salmon, and mackerel contain the largest amounts of LC-PUFA, but pharmaceutical therapeutic options are also available for the treatment of HTG, including highly concentrated fish oil such as Lovaza (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc, Liberty Corner, NJ).

Early investigations into the favorable effects of fish oils primarily attributed benefits to EPA, ignoring the presence of substantial amounts of DHA.^{15,16} This was an understandable assumption as these early studies typically used menhaden oil, the only dietary source commercially available at the time.¹⁶⁻¹⁸ Because menhaden oil consists of more EPA than DHA (18% vs. 9.6% of total fatty acids),¹⁹ many researchers concluded that EPA rather than DHA delivered the benefits. The relative contribution of each omega-3 fatty acid to cardiovascular protection remained to be defined. Recent data, however, demonstrate that both DHA and EPA individually have important cardio-protective properties. Mori and Woodman²⁰ considered the independent effects of EPA and DHA on cardiovascular risk factors. Their review compared results of studies using DHA + EPA with those of DHA alone (including DHA from fish oil) and with one study of EPA alone (Epadel; Mochida Pharmaceutical Company, Tokyo, Japan). They identified important antiarrhythmic, antithrombotic, and antiatherogenic effects of DHA.²⁰ However, the review was limited to only 6 studies using DHA in healthy subjects.

This review summarizes the efficacy and safety of DHA TG oil derived from algae (algal-DHA) specifically for TG reduction and secondly for certain biomarkers and/or risk factors for cardiovascular disease in 16 clinical trials in humans in which algal-DHA-rich oils were derived from either 1 of 2 specific strains of microalgae: *Cryptocodinium cohnii* (DHASCO) and *Schizochytrium sp.* (DHASCO-S) (Martek Biosciences Corporation, Columbia, MD).

Eleven studies considered DHASCO and 5 evaluated DHASCO-S. The DHA in these algal oils is a TG form in the amount of approximately 35%–40% DHA by weight. Small amounts of saturated and monounsaturated fatty acids along with some minor amounts of nonsaponifiable materials are included in these oils (Table 1). These TG oils do not contain significant amounts of EPA. Compared with DHASCO, DHASCO-S has more docosapentaenoic acid (DPA_n6, 22:5n-6) but the amount of DHA in each oil is approximately equivalent. Because algal-DHA is not derived from fish, it is essentially free of oceanic contaminants such as methylmercury, dioxins, or polychlorinated biphenyls. There are a number of “DHA-enriched oils” presently available, but those oils are derived from fish; consequently, studies with those oils were not considered for the

Table 1. Composition of DHASCO and DHASCO-S.

Fatty acid composition (%)		DHASCO*	DHASCO-S†
10:0	Capric acid	2.1	0.0
12:0	Lauric acid	5.4	0.3
14:0	Myristic acid	15.5	7.7
16:0	Palmitic acid	14.6	23.1
16:1n-7	Palmitoleic acid	1.6	0.4
18:0	Stearic acid	0.6	0.7
18:1n-9	Oleic acid	14.9	0.4
18:1n-7	Vaccenic acid	<0.1	0.4
18:2n-6	Linoleic acid	0.8	0.5
18:3n-3	α -linolenic acid	<0.1	0.1
18:4n-3	Stearidonic acid	0.0	0.4
20:0	Arachidic acid	<0.1	0.0
20:3n-6	Di-homogammalinolenic acid	<0.1	0.5
20:4n-6	Arachidonic acid	<0.1	1.1
20:4n-7	Eicosatetraenoic acid n-7	0.0	1.7
20:4n-3	Eicosatetraenoic acid n-3	0.0	1.0
20:5n-3	EPA	<0.1	2.5
22:4n-9	Docosatetraenoic acid	0.0	0.4
22:5n-6	Docosapentaenoic acid n-6	0.0	16.4
22:5n-3	Docosapentaenoic acid n-3	0.2	0.4
22:6n-3	Docosahexaenoic acid	41.5	40.3
Chemical characteristics			
Free fatty acid (%)		<0.4	<0.25
Peroxide value (mEq/kg)		<5	<5
Nonsaponifiables (%)		<3.5	<4.5
Elemental composition (ppm)			
Arsenic		<0.5	<0.5
Copper		<0.1	<0.1
Iron		<0.5	<0.5
Lead		<0.2	<0.2
Mercury		<0.2	<0.2
Phosphorous		<10	<0.2

*From *Cryptocodinium cohnii*.

†From *Schizochytrium sp.*

present review. Algal-DHA may be considered for future therapeutic approaches for treating HTG.

CLINICAL TRIALS

Plasma lipids and lipoproteins

Early clinical trials evaluated the TG-lowering effects of algal-DHA in healthy individuals (Table 2). More recent studies have included efficacy and safety trials in individuals with HTG or with persistent HTG while being treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).

Table 2. Clinical studies of TG levels with algal-DHA.

Study Design	Population n*	Diet/Dose (g/d) Duration	Baseline TG (mg/dL)	Mean Change (%)		
				TG	LDL-C	HDL-C
Normal TG						
Conquer and Holub ²¹	Healthy	DHA 1.62	85	-17†	-7	+17†
RCT: DB Parallel	Vegetarians 24	Placebo 0 6 wk	72	+14†	+9†	+7†
Geppert et al ²²	Healthy	DHA¶ 0.94	96	-23†§	+11†§	+7†§
RCT: DB, Parallel	Vegetarians 106	Placebo 0 8 wk	95	0	-1	-1
Wu et al ²³	Healthy	DHA‡ 2.14	124	-18	-3	+6
RCT: SB, Parallel	Vegetarians 25	Placebo 0 6 wk	134	+3	+4	+4
Agren et al ²⁴	Healthy 55	Fish Diet	120	-15†§	+9	0§
RCT: SB, Control		EPA 0.38				
		DHA 0.67	107	-19†§	+10†	-8
		Fish Oil				
		EPA 1.33				
		DHA 0.95				
		DHA 1.68	104	-17†§	-3	+7§
		Control 0 15 wk	116	+8	-3	-17
Nelson et al ^{25,27}	Healthy 6	Diet DHA <0.05	109	-12	-1	-9
Ferretti et al ²⁶		DHA 6.0 12 wk	73	-26†	-1	+9†
RCT: SB, Control						
Conquer and Holub ²⁸	Healthy 19	DHA 0.75	125	-9	-9	+5
Parallel		DHA 1.5	92	-6	+3	-5
		Placebo 0 6 wk	90	+23	-9	+2
Stark and Holub ²⁹	Healthy 32	DHA 2.8	143	-20†§	+9	+8†
RCT: DB, Crossover		Placebo 0 4 wk	143	-3	+3	+3†
Theobald et al ^{30,31}	Healthy 38	DHA 0.7	91	-2	+10†	+5
RCT: DB Crossover		Placebo 0 12 wk	94	+12	+3	+1
Sanders et al ³²	Healthy 79	DHA‡ 1.5	96	-14†	+7†	+7†
RCT: DB, Parallel		Placebo 0 4 wk	82	-2	-3	+2
Elevated TG						
Davidson et al ³³	Combined	DHA 1.25	250	-21†	+9	+6†
RCT: DB, Parallel	Hyperlipidemia 27	DHA 2.50	296	-18†	+14†	+6†
		Placebo 0 6 wk	236	+4	-2	+6
Engler et al ^{10,34}	Familial	DHA 1.2	120	-5	+8	+5
RCT: DB, Crossover	Hyperlipidemia 20	Placebo 0 6 wk	120	-3	+3	+7
Kelley et al ^{1,35}	Elevated TG 34	DHA 3.0	247	-24†	+15†	+7
RCT: DB, Parallel		Placebo 0 12 wk	257	-8	0	+3
Schwellenbach et al ³⁶	Persistent HTG	Fish Oil	292	-18†	+9	0
RCT: DB, Parallel	with Statins 116	EPA 0.252				
		DHA 1.0				
		DHA‡ 1.0 8 wk	283	-22†	+8	+6†
Keller et al ³	Persistent HTG	DHA 2.0	268	-19†	0	+5†
RCT: DB, Parallel	with Statins 40	Placebo 0 6 wk	325	+3†	-9†	-2†

ALT = alanine transaminase; DB = double-blind; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; HDL-C = high-density lipoprotein cholesterol; HTG = hypertriglyceridemia; LDL-C = low-density lipoprotein cholesterol; RCT = randomized controlled trial; SB = single-blind; TG = triglyceride.

Except for the studies conducted by Geppert et al²² and by Wu et al²³, Martek Biosciences Corporation provided algal-DHA to investigators upon request.

*Number of patients considered in the statistical analyses.

†Statistically significant from baseline values ($P \leq 0.05$).

‡Statistically significant from control ($P \leq 0.05$).

‡Used *Schizochytrium sp* oil; all other studies used *Cryptocodinium cohnii* oil.

¶Used *Ulkenia sp.* oil which is equivalent to *Schizochytrium sp* oil.

Three clinical trials evaluated effects of algal-DHA supplementation on serum lipids, lipoproteins, and risk factors for heart disease in vegetarian subjects.^{21–23} Vegan/vegetarian diets are typically devoid of or deficient in LC-PUFA, allowing evaluation of the independent effects of replenishment and/or supplementation of DHA. Although the precursor of DHA, α -linolenic acid is the major omega-3 fatty acid in the vegan diet, the efficiency of conversion of this fatty acid to DHA is low.²¹ The studies indicated that among vegan subjects with relatively low TG levels at baseline (0.96–1.40 mmol/L), daily supplementation ranging from 0.94 to 2.14 g/d reduced TG levels by 17%–23% and increased high-density lipoprotein cholesterol (HDL-C) by 6%–17%. Two of 3 studies showed a modest decrease in the level of low-density lipoprotein cholesterol (LDL-C).^{21,23} The level of LDL-C increased in vegans who had low TG levels at baseline and who received the lowest dose of algal-DHA.²²

DHA supplementation reduced levels of TG in all 6 studies that considered healthy (nonvegetarian) individuals by approximately 2%–26%.^{24–32} The largest decrease occurred in subjects with the highest baseline TG level (1.61 mmol/L, 143 mg/dL) or who received the largest dose of algal-DHA (6 g/d). In all but one study,²⁸ the level of HDL-C increased by 5%–9% but the change in LDL-C was inconsistent and not statistically significant.

Agren et al²⁴ compared supplementation with 1.68 g/d of algal-DHA with fish oil (1.33 g/d EPA + 0.95 g/d DHA) or a diet that included 4 servings of fish per week (0.38 g/d EPA + 0.67 g/d DHA). Relatively large, significant decreases in the level of TG (15%–19%) were observed in all test groups, but algal-DHA supplementation modestly reduced the level of LDL-C (3%) and significantly increased the level of HDL-C (7%).

In 3 other studies, subjects with initially low HDL-C, with combined hyperlipidemia or with childhood familial hyperlipidemia (high cholesterol), were evaluated. In all 3 studies, the level of TG decreased and the level of HDL-C increased.^{10,33–36} Although the level of LDL-C increased by as much as 15%, the LDL-C rise associated with the LC-PUFA-mediated TG reduction was attributable to a shift in lipoprotein particle size from the small, atherogenic to the larger, more buoyant and less atherogenic particle size.^{1,3,34,35,37–39}

There was a reported significant increase in the number of large, buoyant LDL₁ and HDL₂ particles and an accompanying decrease in the number of small, dense LDL₃ particles.^{10,34} In combination, these changes resulted in a significant decline in the percentage of cholesterol that is carried by small, dense particles. A greater number of small, dense atherogenic LDL particles has been associated with an increased risk of

cardiovascular events.⁴⁰ This risk may reflect an increased susceptibility of the small LDL particles to oxidation and a tendency to infiltrate the arterial wall which may cause foam cell formation and inflammation.^{41,42} Mesa et al⁴³ reported that DHA alone from fish oil decreases the susceptibility of LDL to oxidation and may inhibit an early event linked to the progression of atherosclerosis to the same degree as reported for EPA.

A slightly different serum lipid profile was observed in the 2 studies that considered subjects with persistent HTG while being treated with statins.^{3,36} Levels of TG decreased by up to 22% and HDL-C increased by 5%–6%, demonstrating an additive benefit with statins. LDL-C was unchanged in one study in which 2 g/d was administered³ whereas LDL-C increased by 8% in the other that used 1 g/d.³⁶ Schwellenbach et al³⁶ compared the effects of DHA alone with those from fish oil and reported similar reductions in TG levels, but the algal-DHA significantly increased HDL-C by 6% whereas the level of HDL-C in the fish oil group was unchanged. Notably, a significant reduction in the level of total cholesterol was observed only in those studies whose subjects received both algal-DHA or DHA/EPA and statins (data not shown).

ANALYSIS OF TG REDUCTION FROM ALGAL-DHA SUPPLEMENTATION

Using data from 15 of 16 studies considered in the present study, linear regression analysis (SigmaPlot from Systat Software, Inc, Chicago, IL) was used to determine the effect that different doses of algal-DHA had on the percent change from baseline of TG levels (Fig. 1) and the effect that baseline TG levels had on the absolute change of TG levels (Fig. 2) when algal-DHA was administered. The study by Wheaton et al⁴⁴ was not used because it did not provide baseline data for TG levels. Algal-DHA supplementation significantly reduced fasting TG levels in a dose-dependent fashion, regardless of the type of algal oil used or level of baseline TG. It seems that supplementation of 1–2 g/d of algal-DHA, with or without concomitant statin therapy, effectively lowered TG level by 15%–20%. The absolute decrease (mg/dL) in the level of TG in subjects with HTG was markedly greater than in that observed in subjects with normal levels of TG.

BLOOD PRESSURE, HEART RATE, AND OTHER RISK FACTORS FOR CARDIOVASCULAR DISEASE

There is an unequivocal evidence that LC-PUFA offer a modest reduction in blood pressure, particularly in




FIGURE 1. Regression analysis of percent change from baseline in TG levels vs. dose of algal-DHA.

hypertensive individuals. Mori et al⁴⁵ showed that DHA from fish oil, but not EPA, relative to placebo significantly lowered 24-hour ambulatory systolic and diastolic blood pressure and heart rate in overweight, mildly hyperlipidemic men. Two studies considered here reported that algal-DHA reduced systolic and diastolic blood pressure and heart rate (Table 3). Kelley et al¹ reported that among men with HTG, supplementation with 3 g/d of algal-DHA for 45 days significantly reduced heart rate by 8.3% and systolic




FIGURE 2. Regression analysis of absolute change from baseline in TG levels vs. baseline TG levels.

and diastolic blood pressure by 5.6% and 4.0%, respectively, compared with measurements taken at baseline. Heart rate fell by 9% and diastolic blood pressure by 19% among statin-treated cardiac patients who were administered 2 g/d of algal-DHA for 6 weeks.³ Stark and Holub²⁹ reported that treatment with 2.8 g/d of algal-DHA for 4 weeks was associated with a 7% decline in heart rate but not blood pressure among postmenopausal women receiving and not receiving hormone replacement therapy.

The study by Engler et al¹⁰ in 9- to 19-year-old children with familial hypercholesterolemia or the phenotype of familial combined hyperlipidemia demonstrated that 1.2 g/d of algal-DHA for 6 weeks improved endothelium-dependent flow-mediated dilation of the brachial artery compared with baseline and placebo; flow-mediated dilation of the brachial artery function was similar to that observed in normal levels in healthy children. It seems that young hyperlipidemic children show attenuated endothelial function as a consequence of reduced nitric oxide bioavailability.⁴⁶ If large, buoyant LDL particles enriched with DHA are more resistant to oxidation, then there may be increased nitric oxide bioavailability by increasing its production or decreasing its degradation in the endothelium.³⁴ The vasorelaxant effect of DHA may also increase nitric oxide synthesis or release.¹⁰ By increasing nitric oxide bioavailability, DHA may have the potential to delay the early onset of coronary heart disease in hyperlipidemic children.¹⁰

The effects of a fish-enriched diet or dietary supplements of fish oil or algal-DHA on platelet aggregation and homeostatic factors were studied in healthy men.^{24,47} The results indicated that a fish diet and fish oil, but not algal-DHA, inhibited *in vitro* platelet aggregation, but hemostatic factors were not affected by the n-3 fatty acid supplementation. Sanders et al³² also reported no significant differences between the algal-DHA group and placebo in serum C-reactive protein, plasma VII antigen, activated FVII, fibrinogen, von Willebrand factor, plasminogen activator inhibitor-1, and markers for muscle damage and cardiac muscle damage (creatin kinase and troponin-I activities). Supplements of 1.62 g/d of algal-DHA in healthy vegetarians also failed to reduce collagen- and adenosine diphosphate-induced aggregation or collagen-stimulated thromboxane A₂ release.²¹ Compared with baseline values, higher doses of algal-DHA (6 g/d) administered to healthy men for 90 days reduced urinary thromboxane B₂ excretion.²⁶ However, the prothrombin time, activated thromboplastin time, and the antithrombin-III levels before and after supplementation with 6 g/d of algal-DHA were not significantly different.²⁷ Additionally, the *in vivo* bleeding times did

Table 3. Effects of algal-DHA on biomarkers and/or other risk factors for cardiovascular disease.

Study	Population	Effect(s)
Normal TG Conquer and Holub ²¹	Healthy vegetarians	Collagen-induced platelet aggregation, collagen-induced thromboxane A ₂ , serum viscosity, fibrinogen, and factor VIIc levels were not significantly altered.
Geppert et al ²² Agren et al ^{24,47}	Healthy vegetarians Healthy	No effect on BP or HR. Reduced Apo B levels in the VLDL fraction. No statistically significant effect on platelet aggregation.
Nelson et al ^{25,27} ; Ferretti et al ²⁶	Healthy	Apo-A1, apo B, and Lp(a) showed very little change after the high-DHA diet. No changes in blood coagulation, platelet function, or thrombotic tendencies.
Conquer and Holub ²⁸ Stark and Holub ²⁹	Healthy Normal	No effect on Lp(a), BP, or HR. DHA reduced heart rate by 5 beats/min; systolic and diastolic BP and MAP decreased, but statistical significance was considered a main effect of time rather than supplementation status.
Theobald et al ^{30,31}	Normal	The cholesterol:Apo B ratio was greater after DHA treatment, which may suggest that the LDL particle size was increased. DHA lowered diastolic BP; HR tended to be 2.1 beats/min lower after DHA.
Sanders et al ³² Elevated TG	Healthy	No effect on creatinine kinase and troponin-I activities.
Davidson et al ³³	Combined hyperlipidemia	Increase in non-HDL-C only observed at the higher dose of algal-DHA (2.5 g/d).
Engler et al ^{10,34}	Familial hyperlipidemia	Increased large, buoyant LDL ₁ by 91% and HDL ₂ by 14% compared with placebo. Small dense LDL ₃ decreased by 48% compared with placebo. FMD increased significantly after DHA.
Kelley et al ^{1,35}	HTG	DHA reduced heart rate and systolic and diastolic blood pressure. DHA did not affect Apo B but reduced the number of small LDL particle size and increased the number of large particles. DHA decreased RLP-C and increased RBC n-3 index.
Schwellenbach et al ³⁶	Persistent HTG while treated with statins	Decreased non-HDL-C level in both groups.
Keller et al ³	Persistent HTG while treated with statins	Decrease in small LDL particles and increase in large LDL particles. DHA reduced heart rate and decreased diastolic blood pressure and non-HDL-C levels.
Low HDL Maki et al ³⁷	Low HDL ≤44 mg/dL (men) and ≤54 mg/dL (women) but ≥35 mg/dL	Reduction in small dense LDL ₃ + LDL ₄ particles and increase in number of larger, less dense LDL ₁ + LDL ₂ particles.

BP, blood pressure; DHA, docosahexaenoic acid; FMD, flow-mediated dilation of the brachial artery; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; Lp(a), lipoprotein(a); MAP, mean arterial pressure; RBC, red blood cell; RLP-C, plasma remnant-like particle cholesterol; VLDL, very low density lipoprotein.

not show any significant difference during and after algal-DHA supplementation.²⁷

Kelley et al³⁵ considered 2 novel risk factors for cardiovascular disease: plasma remnant-like particle cholesterol and the red blood cell (n-3) index (sum of DHA and EPA as a percent of total fatty acid content) in men with HTG. Remnant-like particles that are produced from very low density lipoproteins are the major atherogenic lipoproteins that can be taken up by

macrophages to produce foam cells without oxidative modification.^{35,48} Algal-DHA supplementation of 3 g/d for 45 days decreased fasting plasma remnant-like particle cholesterol by 36% and increased the red blood cell (n-3) index by 109%.³⁵ Continued supplementation between days 45 and 91 further increased the red blood cell (n-3) index (162%) compared with baseline values.

The Third Adult Treatment Panel of the National Cholesterol Education Program identified elevated

LDL-C as the primary target of lipid-lowering therapy.⁴⁹ A new secondary target of therapy was also introduced, namely, non-high-density lipoprotein cholesterol (non-HDL-C) in patients with elevated TG levels (≥ 200 mg/dL).^{49,50} Non-HDL-C was added as a secondary target of therapy to account for the atherogenic properties associated with remnant lipoproteins in patients with HTG.^{49,50} Davidson et al³³ reported a significant increase in non-HDL-C (+5.7%) from baseline at the higher dose of algal-DHA (2.5 g/d), but not at the lower dose (1.25 g/d), in subjects with combined hyperlipidemia. However, Schwellenbach et al³⁶ reported a significant decrease in non-HDL-C compared with placebo when subjects with HTG were taking statins and either 1 g/d of algal-DHA or 1.25 g/d of fish oil (-4.8% and -3.7%, respectively).

Apolipoprotein B (Apo B) is a potential marker for atherogenic lipoproteins.⁴⁹ It has been proposed that Apo B may serve as an alternative to LDL-C as a risk factor, but the preponderance of evidence in favor of Apo B has not been developed sufficiently to justify replacing LDL-C as a primary risk factor.⁴⁹ In subjects with normal levels of TG, LDL-C is highly correlated with Apo B but the level of Apo B is much higher in subjects with HTG.⁴⁹ In the 4 studies that considered the level of Apo B, Agren et al²⁴ reported that Apo B levels decreased only in the very low density lipoprotein fraction among subjects in the fish diet and algal-DHA groups. Both Nelson et al²⁵ and Kelley et al¹ indicated that algal-DHA treatment did not affect levels of Apo B. Theobald et al³⁰ reported a significant increase in the level of Apo B in the algal-DHA group. However, the LDL-C:apo B ratio was greater, suggesting a shift toward the larger less atherogenic LDL particle size.

There is a significant association between level of lipoprotein(a) (Lp(a)) and risk of cardiovascular disease.^{51,52} However, there is no evidence from clinical trials that supports a benefit from lowering Lp(a) levels with different therapies.⁴⁹ Only nicotinic acid therapy reduces Lp(a) levels, but only moderately.⁵³ Two studies reported data for Lp(a) levels in healthy subjects who received algal-DHA treatment.^{25,28} Both studies indicated that algal-DHA supplementation did not affect levels of Lp(a). However, Nelson et al²⁵ reported that Lp(a) levels rose significantly in the control group.

SAFETY AND TOLERABILITY OF ALGAL-DHA

The safety of algal-DHA is well established. The Food and Drug Administration has affirmed that DHA and/or EPA at intakes of up to 3 g/d are "Generally

Recognized as Safe."⁵⁴ Both DHASCO and DHASCO-S fall under these guidelines and are considered Generally Recognized as Safe.

In clinical trials, algal-DHA is found to be well tolerated. Adverse events are uncommon and limited to mild gastrointestinal complaints such as eructation or occasional taste perversion. Schwellenbach et al³⁶ compared the safety and tolerability of DHA and fish oil. A significantly greater proportion of subjects in the fish oil group reported fishy taste as a problem.

An ongoing long-term study of X-linked retinitis pigmentosa in 44 young men (mean age = 16 years) has reported 4-year safety data in subjects who received either 400 mg/d of algal-DHA or placebo.⁴⁴ All adverse events were minor and equally distributed between the DHA and placebo groups. Long-term algal-DHA supplementation did not compromise plasma antioxidant capacity, platelet aggregation, liver function enzyme activity, or plasma lipoprotein content.

CONCLUSIONS

Clinical trials with algal-DHA as a TG oil have demonstrated a marked reduction in serum TG levels (up to 26%) in normal individuals and in those with HTG or combined hyperlipidemia. It seems that supplementation of 1-2 g/d of algal-DHA with concomitant statin therapy not only lowers TG level by an additional 19%-22% but also raises HDL-C and lowers non-HDL-C, demonstrating an important additive effect. Algal-DHA has also been shown to be safe and well tolerated. The study that compared algal-DHA with fish oil reported that algal-DHA seems to be less likely to cause complaints associated with a fishy taste.

Algal-DHA also seems to be consistent in increasing LDL particle size, a finding that may represent an additional antiatherogenic effect. Algal-DHA seems to be effective in modestly reducing blood pressure and heart rate. The effects may be related to improvements in endothelial relaxation and attenuated vascular constriction. Mori and Woodman²⁰ noted that EPA is not as effective as DHA with respect to blood pressure reduction. At doses <3 g/d, algal-DHA did not compromise bleeding time or platelet aggregation.

Further studies are needed to evaluate the efficacy and safety of algal-DHA for treating subjects with very high levels of TG (>5.64 mmol/L, 500 mg/dL). Although it is clear that effectiveness of TG reduction is both dose dependent and related to initial TG level, further studies are needed to establish the minimum dose of algal-DHA needed for effectiveness, especially in populations with very high TG levels. Notably, this

review shows that the benefits accomplished using fish oil in subjects with HTG may also be attainable with a vegetarian source of algal-DHA as a TG oil.

REFERENCES

1. Kelley DS, Siegel D, Vemuri M, et al. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic man. *Am J Clin Nutr.* 2007;86:324–333.
2. Bonna KH, Thelle DS. Association between blood pressure and serum lipids in a population. *Circulation.* 1991;83:1305–1314.
3. Keller DD, Jurgilas S, Perry B, et al. Docosahexaenoic acid (DHA) lowers triglyceride levels and improves low density lipoprotein particle size in a statin-treated cardiac risk population. *J Clin Lipidol.* 2007;1:151.
4. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden death. *JAMA.* 1998;279:23–28.
5. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet.* 1999;354:447–455.
6. Mori TA, Beilin LJ. Ω 3 fatty acids and inflammation. *Curr Atheroscler Rep.* 2004;6:461–467.
7. Galli C, Tremoli E, Sirtori C. n-3 fatty acids: incorporation into tissue lipids and interactions with dietary components. In: De Caterina R, Kristensen SD, Schmidt ED, eds. *Fish Oil and Vascular Disease.* Verona, Italy: Bi & Gi Publishers; 1992:35–41.
8. Eritsland J, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. *Am J Cardiol.* 1996;77:31–36.
9. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. *Circulation.* 2000;102:1264–1269.
10. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY Study. *Int J Clin Pharmacol Ther.* 2004;42:672–679.
11. Daviglius ML, Stamler J, Orenca AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. *N Eng J Med.* 1997;336:1046–1053.
12. Zhang J, Sasaki S, Amano K, et al. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. *Prev Med.* 1999;28:520–529.
13. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. *JAMA.* 2002;287:1815–1821.
14. American Heart Association. Fish and omega-3 fatty acids (AHA Recommendations). American Heart Association web site. Available at: <http://www.heart.org/presenter.jhtml?identifier = 4632>. Accessed December 28, 2007.
15. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. *Lancet.* 1971;1:1143–1145.
16. Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. *Adv Nutr Res.* 1980;3:1–22.
17. Hirai A, Hamazaki R, Terano T, et al. Eicosapentaenoic acid and platelet function in Japanese. *Lancet.* 1980;2:1132–1133.
18. Yotakis LDO. The preventive effects of polyunsaturated fats on thrombosis. *Thromb Haemost.* 1981;46:65–68.
19. Shahidi F, Miraliakbari H. Marine oils; compositional characteristics and health effects. In: Shahidi F, ed. *Nutraceuticals and Specialty Lipids and Their Co-Products.* London: Taylor & Francis; 2006:229.
20. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. *Curr Opin Clin Nutr Metab Care.* 2006;9:95–104.
21. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. *J Nutr.* 1996;126:3032–3039.
22. Geppert J, Kraft V, Demmelmair H, et al. Microalgal docosahexaenoic acid reduces plasma triacylglycerol in normolipidemic vegetarians: a randomized trial. *Br J Nutr.* 2006;95:779–786.
23. Wu WH, Lu SC, Wang TF, et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and *in vivo* oxidative stress in postmenopausal vegetarian women. *Eur J Clin Nutr.* 2006;60:386–392.
24. Agren JJ, Hanninen O, Julkunen A, et al. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. *Eur J Clin Nutr.* 1996;50:765–771.
25. Nelson GJ, Schmidt PC, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans. *Lipids.* 1997;32:1137–1146.
26. Ferretti A, Nelson J, Schmidt PC, et al. Dietary docosahexaenoic acid reduced the thromboxane/prostacyclin synthesis ratio in humans. *J Nutr Biochem.* 1998;9:88–92.
27. Nelson GJ, Schmidt PS, Bartolini GL, et al. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation. *Lipids.* 1997;32:1129–1136.
28. Conquer JA, Holub BJ. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. *J Lipid Res.* 1998;39:286–292.
29. Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. *Am J Clin Nutr.* 2004;79:765–763.

30. Theobald HE, Chowienyck PJ, Whittall R, et al. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. *Am J Clin Nutr.* 2004;79:558–563.
31. Theobald HE, Goodall AH, Sattar N, et al. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. *J Nutr.* 2007;137:973–978.
32. Sanders TAB, Gleason K, Griffen B, et al. Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. *Br J Nutr.* 2006;95:525–531.
33. Davidson MH, Maki KC, Kalkowski J, et al. Effect of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr.* 1997;16:236–243.
34. Engler MM, Engler MB, Malloy MJ, et al. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY Study). *Am J Cardiol.* 2005;95:869–871.
35. Kelley DS, Siegel D, Vemuri M, et al. Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. *J Nutr.* 2008;138:30–35.
36. Schwellenbach LJ, Olson KL, McConnell KJ, et al. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides. *J Am Coll Nutr.* 2006;25:480–485.
37. Maki KC, Van Elswyk ME, McCarthy D, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. *J Am Coll Nutr.* 2005;24:189–199.
38. Suzukawa M, Abbey M, Howe PR, et al. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. *J Lipid Res.* 1995;36:473–484.
39. Sorensen NS, Marckmann P, Hoy C-E, et al. Effect of fish-oil-enriched margarine on plasma lipids, low-density-lipoprotein particle composition, size, and susceptibility to oxidation. *Am J Clin Nutr.* 1998;68:235–241.
40. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary heart disease in men and women. *JAMA.* 1996;276:875–881.
41. Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. *Atherosclerosis.* 1992;93:189–199.
42. Nielsen TB. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. *Atherosclerosis.* 1996;123:1–15.
43. Mesa MD, Buckley R, Minihaue AM, et al. Effects of oils rich in eicosapentaenoic and docosahexaenoic acid on the oxidizability and thrombogenicity of low-density lipoprotein. *Atherosclerosis.* 2004;175:333–343.
44. Wheaton DH, Hoffman DR, Locke KG, et al. Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa. *Arch Ophthalmol.* 2003;121:1269–1278.
45. Mori TA, Bao DQ, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. *Hypertension.* 1999;34:253–260.
46. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. *J Clin Invest.* 1999;103:879–905.
47. Agren JJ, Vaisanen S, Hanninen O, et al. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. *Prostaglandins Leukot Essent Fatty Acids.* 1997;57:419–421.
48. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. *Clin Chim Acta.* 2006;367:36–47.
49. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *10Circulation.* 2002;106:3143–3421.
50. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation.* 2004;110:227–239.
51. Budde T, Fechttrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically-suspected coronary atherosclerosis. *Arterioscler Thromb.* 1994;14:1730–1736.
52. Seman LJ, DeLuca C, Jenner JL, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. *Clin Chem.* 1999;45:1036–1046.
53. Angelin B. Therapy for lowering lipoprotein(a) levels. *Curr Opin Lipidol.* 1997;8:337–341.
54. Food and Drug Administration, Department of Health and Human Services. Substances affirmed as Generally Recognized as Safe: menhaden oil. *Fed Regist.* 1997;62:30751–30757.